Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous RNA-electroporated mature dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- Radboud University Medical Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Intradermal
01
Overview
The autologous RNA-electroporated mature dendritic cell vaccine is an investigational, patient-specific cellular immunotherapy developed by Radboud University Nijmegen Medical Centre for the treatment of multiple myeloma. The manufacturing process involves isolating monocytes from the patient via apheresis, differentiating them into mature dendritic cells (DCs), and subsequently electroporating the DCs with mRNA encoding three tumor-associated antigens (TAAs): MAGE-3, Survivin, and B-cell maturation antigen (BCMA). Keyhole limpet hemocyanin (KLH) is added as an immunological adjuvant and tracer. The vaccine is designed to stimulate a T-cell mediated immune response against myeloma cells expressing these TAAs. In clinical evaluation, it has been administered to patients in minimal residual disease (MRD) following autologous stem cell transplantation to assess safety and immunogenicity.
- Other names
- autologous mature dendritic cells electroporated with RNA encoding MAGE-3, survivin, and BCMARNA-electroporated DC vaccine
02
Targets
MAGEC2 (Melanoma-associated antigen C2)PMEL (Melanocyte Protein PMEL)TYR (Tyrosinase)MAGEA3 (Melanoma-associated antigen 3)
Beyond the preview
Go deeper on autologous RNA-electroporated mature dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous RNA-electroporated mature dendritic cell vaccine.